The UK is, indeed, the one to watch. It's their National Institute for Clinical Effectiveness (NICE) Covid team that initiated discussion with Humanigen. I think their NIH may have done so, as well. Compare that initiation to our own bureaucratic responses. An extremely long time for a NASDAQ uplisting decision; patient enrollment practically coming to a halt for a month while Big Pharma staffed their trials; the lowered Hazard Ratios for the small cap bios after Phase III trials, etc. And frankly, I have to think the company could have probably applied for the EUA a little sooner than they did. We did see how quickly the FDA approved the Gilead EUA for remdesivir, so we could be pleasantly surprised. Well, that's an understatement of how I would take the news, I would be absolutely shocked with a quick approval. But the FDA can act quickly, especially in Covid related cases.
I'm afraid that I don't understand how a treatment could be achieved with as little as 3 vials, based on the information we've been discussing in this thread. I would think 18 vials per dose. But that doesn't seem very practical. Your mention of a possibility that we could see alternative packaging besides liters and vials is the first such suggestion I have seen here.
To focus on the 1st world markets initially makes strategic business sense.
But to me, it makes very, very little sense to start commercialization with 100k or even 200k treatments. I doubt they could even satisfy the US National Stockpile requirements with that volume. I can understand that that may represent all that the company, by itself, can do. But why would our government agency partners not have recognized the unmet demand, and made it their focus to help Humanigen get lenz produced to meet that demand? We can produce 100's of millions of vaccines, but do no better than 100k or 200k patient treatments?
Is our approach going to be mercenary, or merciful?
